SCHEMBL19010288

SCHEMBL19010288

CC(=O)c1nnc(Nc2ccc(N3CCN(C(C)=O)CC3)cc2)cc1NCc1cccc(C)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 5/20 0.68
MAPT P10636 8/20 0.52
GAA P10253 7/20 0.52
ALOX15 P16050 6/20 0.52
ALOX12 P18054 6/20 0.52
MAPK1 P28482 3/20 0.52
KDM4E B2RXH2 6/20 0.51
ALDH1A1 P00352 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 2/20 0.51
NPC1 O15118 1/20 0.48
PKM P14618 1/20 0.48
SYK P43405 2/20 0.47
TDP1 Q9NUW8 4/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TSHR P16473 2/20 0.46
HTT P42858 2/20 0.46
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17021289 0.93 GFER (0.66) GFERMAPTGAAALOX15ALOX12
SCHEMBL19010243 0.91 MAPT (0.64) GFERMAPTGAAALOX15ALOX12
SCHEMBL19010292 0.90 GFER (0.54) GFERMAPTGAAALOX15ALOX12
SCHEMBL19010276 0.90 GFER (0.54) GFERMAPTGAAALOX15ALOX12
SCHEMBL19010305 0.89 GFER (0.52) GFERMAPTGAAALOX15ALOX12
SCHEMBL19010319 0.88 ENPP2 (0.59) GFERMAPTGAAALOX15ALOX12
SCHEMBL19010322 0.88 MAPT (0.59) GFERMAPTGAAALOX15ALOX12
SCHEMBL19010315 0.88 GFER (0.51) GFERMAPTGAAALOX15ALOX12
SCHEMBL19010309 0.86 MAPT (0.52) GFERMAPTGAAALOX15ALOX12
SCHEMBL19010313 0.86 GFER (0.49) GFERMAPTGAAALOX15ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834548-B2 Pyridazine compounds as JAK inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2017-12-05 US disclosed
US-20170174673-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS ALEXION PHARMACEUTICALS, INC. 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174673-A1 PYRIDAZINE COMPOUNDS AS JAK INHIBITORS JAK1, JAK2, JAK3 GFER 3845/4885MAPT 53/4885GAA 2694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.